The expression of MEG3 has been shown to be altered in many human cancers, such as non-small cell lung cancer (NSCLC), hepatocellular carcinoma, meningiomas, gastric cancer and pituitary tumors [3, 12, 14, 24, 25]. This evidence concerns the gene MEG3 and non-small cell lung carcinoma.